179 related articles for article (PubMed ID: 32172510)
1. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
[TBL] [Abstract][Full Text] [Related]
2. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
Goyal RK; Cuyun Carter G; Nagar SP; Nash Smyth E; Price GL; Parikh RC; Huang YJ; Li L; Davis KL; Kaye JA
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):699-710. PubMed ID: 32755262
[TBL] [Abstract][Full Text] [Related]
4. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
5. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
7. HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.
Piccinni C; Dondi L; Ronconi G; Calabria S; Pedrini A; Esposito I; Martini N; Marangolo M
Clin Drug Investig; 2019 Oct; 39(10):945-951. PubMed ID: 31347036
[TBL] [Abstract][Full Text] [Related]
8. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
9. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
[TBL] [Abstract][Full Text] [Related]
10. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
11. Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.
Engel-Nitz NM; Hao Y; Becker LK; Gerdes R
J Comp Eff Res; 2015 Aug; 4(4):303-14. PubMed ID: 26274792
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
13. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of metastatic breast cancer in Spain.
Bermejo de Las Heras B; Cortes Ramon Y Cajal J; Galve Calvo E; de la Haba Rodriguez J; Garcia Mata J; Moreno Anton F; Pelaez Fernandez I; Rodriguez-Lescure A; Rodriguez Sanchez CA; Ruiz-Borrego M; Remak E; Barra M; Rivero M; Soto Alvarez J
Eur J Hosp Pharm; 2020 Jan; 27(1):19-24. PubMed ID: 32064084
[TBL] [Abstract][Full Text] [Related]
16. Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents.
Mahtani R; Oestreicher N; Lalla D; Ogbonnaya A; Saundankar V; Willey J; Coutinho AD; McCann K
Clin Breast Cancer; 2022 Jun; 22(4):e488-e496. PubMed ID: 35067467
[TBL] [Abstract][Full Text] [Related]
17. Indirect costs associated with metastatic breast cancer.
Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
[No Abstract] [Full Text] [Related]
19. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
